3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
126
Melanoma
92
Neoplasms
82
Colorectal Neoplasms
62
Squamous Cell Carcinoma of Head and Neck
61
Neoplasm Metastasis
59
Triple Negative Breast Neoplasms
51
Carcinoma, Renal Cell
47
Breast Neoplasms
39
Lung Neoplasms
37
Ovarian Neoplasms
32
Pancreatic Neoplasms
30
Head and Neck Neoplasms
29
Stomach Neoplasms
28
Urinary Bladder Neoplasms
26
Carcinoma, Transitional Cell
26
Endometrial Neoplasms
24
Parkinson Disease 4, Autosomal Dominant Lewy Body
23
Uterine Cervical Neoplasms
21
Carcinoma, Hepatocellular
18
Recurrence
15
Esophageal Neoplasms
15
Prostatic Neoplasms
14
Lymphoma
14
Small Cell Lung Carcinoma
12
Carcinoma, Squamous Cell
12
Kidney Neoplasms
11
Cholangiocarcinoma
11
Advanced Solid Tumor
11
Solid Tumor
10
Interventions
sotorasib
1
pembrolizumab
1
osimertinib
1
nazartinib
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Noonan Syndrome
×
pembrolizumab
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled